Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 9/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19662787 | 0.82 | CREBBP (0.47) | CREBBPLRRK2HTR3A | |
| SCHEMBL21237241 | 0.79 | CREBBP (0.43) | CREBBPLRRK2SOS1HTR3A | |
| SCHEMBL21237250 | 0.78 | CREBBP (0.49) | CREBBPSOS1HTR3AKRAS | |
| SCHEMBL21237477 | 0.76 | CREBBP (0.47) | CREBBPLRRK2 | |
| SCHEMBL21237580 | 0.72 | CREBBP (0.53) | CREBBPSOS1 | |
| SCHEMBL19662790 | 0.71 | CREBBP (0.50) | CREBBPLRRK2SOS1HTR3A | |
| SCHEMBL23762011 | 0.69 | CREBBP (0.47) | CREBBPHTR3A | |
| SCHEMBL19662997 | 0.69 | CREBBP (0.47) | CREBBPHTR3A | |
| SCHEMBL24368090 | 0.69 | SOS1 (0.48) | CREBBPSOS1HTR3AKRAS | |
| SCHEMBL19662984 | 0.69 | CREBBP (0.47) | CREBBPHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | CREBBP 3/4885LRRK2 1327/4885SOS1 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.